Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Vitamin D study #41 of 167   Meta Analysis
10/27 Analysis of outcomes based on serum levels
Hernández et al., The Journal of Clinical Endocrinology & Metabolism, doi:10.1210/clinem/dgaa733 (Peer Reviewed)
Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection
Source   PDF   Share   Tweet
Retrospective 216 COVID-19 patients and 197 population controls, showing vitamin D deficiency in 82.2% of COVID-19 cases and 47.2% of population-based controls (P < .0001). Authors note: "We did not find any relationship between vitamin D concentrations or vitamin deficiency and the severity of the disease". While no association was found within hospitalized patients, there is an association with hospitalization, and hospitalization is an indication of COVID-19 severity.
19 of the COVID-19 patients were taking vitamin D supplements, showing lower ventilation and ICU admission, but no significant difference in mortality.
Hernández et al., 10/27/2020, retrospective, Spain, Europe, peer-reviewed, 12 authors.
risk of combined death/ICU/ventilation, 83.0% lower, RR 0.17, p < 0.001, high D levels 35, low D levels 162, >= 20ng/mL risk of hospitalization * risk of death/ICU/ventilation | hospitalization.
risk of combined death/ICU/ventilation if hospitalized, 12.0% lower, RR 0.88, p = 0.86, high D levels 35, low D levels 162, >= 20ng/mL risk of death/ICU/ventilation | hospitalization.
risk of hospitalization, 80.6% lower, RR 0.19, p < 0.001, >= 20ng/mL.
risk of death, 3.7% higher, RR 1.04, p = 1.00, high D levels 2 of 19 (10.5%), low D levels 20 of 197 (10.2%), supplementation.
risk of mechanical ventilation, 75.9% lower, RR 0.24, p = 0.13, high D levels 1 of 19 (5.3%), low D levels 43 of 197 (21.8%), supplementation.
risk of ICU admission, 79.3% lower, RR 0.21, p = 0.05, high D levels 1 of 19 (5.3%), low D levels 50 of 197 (25.4%), supplementation.
hospitalization time, 33.3% lower, relative time 0.67, p = 0.11, high D levels 19, low D levels 197, supplementation.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 167 studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit